NIKON CORPORATION
7731・Prime Market・Precision Instruments
Business
Nikon Corporation is a precision optical equipment manufacturer founded in 1917, forming a global group with 82 consolidated subsidiaries and 10 equity-method affiliates. Its business is composed of five segments: Imaging Products (mid-to-high-end cameras and interchangeable lenses), Precision Equipment (FPD and semiconductor lithography systems), Healthcare (Life Science Solutions, Eye Care Solutions, and Cell Contract Manufacturing Solutions), Components (Industrial Equipment, optical components, EUV-related), and Digital Manufacturing (metal 3D printers). Its main customers span a wide range of fields, including imaging creators, semiconductor manufacturers, medical institutions, and defense and aerospace companies, and it provides value across diverse industries through its core technologies in light utilization and precision engineering.
Business Model
In the Imaging Products Business, sales of mid-to-high-end cameras and interchangeable lenses are the main revenue source, while the Precision Equipment Business generates revenue from build-to-order lithography system sales and maintenance services. The Healthcare Business, in addition to selling microscopes and ophthalmic equipment, operates cell contract manufacturing services, and the Components Business secures stable revenue through sales of industrial measuring instruments and optical components. The Digital Manufacturing Business is entering the defense and aerospace markets centered on metal 3D printer equipment sales, and is currently in a growth investment phase.
Company Strengths
The company applies optical utilization technology and precision technology as core technologies, developing them into "optical technology," "precision processing technology," "precision measurement technology," "image processing technology," and other areas, commercializing products across multiple fields including imaging, semiconductor lithography, healthcare, industrial measurement, and metal 3D printers. Research and development investment for FY2026 (ending March 2026) reached ¥77,195 million, and a system has been established in which the Technology Strategy Committee (chaired by the CTO) oversees priority investment areas from a medium- to long-term perspective.
The order backlog for the Precision Equipment Business at the end of FY2026 (ending March 2026) stood at ¥112,882 million (up 3.9% year on year), and market expansion has been achieved through the introduction of new products, including the "FX-88SL/SLD," the industry's first FPD Lithography System to adopt a UV-LED light source, and the start of orders for the Digital Lithography System for Semiconductor Back-End Process (DSP-100), "DSP-100." A patent license agreement with ASML and Carl Zeiss (through 2029) also underpins the technological foundation.
The Imaging Products Business posted revenue of ¥290,053 million, the largest among all segments, maintaining stable unit sales and sales value in the mid- to high-end Mirrorless Cameras (Z Series) and Interchangeable Lenses (NIKKOR Lenses) markets. In FY2026 (ending March 2026), the company launched the Digital Cinema Cameras (ZR Series), "ZR," developed through technological integration with RED Digital Cinema, Inc., marking a full-fledged entry into the professional video market. The Imaging Products Business continues to invest resources, with capital expenditure of ¥10,914 million and research and development investment of ¥24,012 million.
ENVALITH's Perspective
Performance Trend
Revenue peaked at ¥717,245 million in FY2024 (ending March 2024) before declining for two consecutive periods, reaching ¥677,163 million in FY2026 (ending March 2026), down 5.3% year on year. Operating profit deteriorated sharply from ¥49,934 million in FY2022 (ending March 2022) → ¥54,908 million in FY2023 (ending March 2023) → ¥39,776 million in FY2024 (ending March 2024) → ¥2,422 million in FY2025 (ending March 2025) → -¥112,448 million in FY2026 (ending March 2026). The main driver of the widened loss in FY2026 was an impairment loss of ¥99,141 million in the Digital Manufacturing Business (of which ¥90,627 million related to Nikon SLM Solutions AG), which includes one-off factors. As external factors, sluggish non-AI-related semiconductor market conditions, stagnation in the US life science market, a slowdown in the EUV-related market, and tariff impacts weighed on revenue across multiple segments. For FY2027 (ending March 2027), the company forecasts a recovery to revenue of ¥740,000 million (up 9.3% year on year) and operating profit of ¥10,000 million, although it still expects an operating loss of ¥7,000 million for the first half.
Growth Strategy
Concentrated investment in three priority fields (digital cinema, large-format metal 3D printers, and ArF immersion/digital lithography) aims to enhance corporate value toward 2030
Nikon launched and began selling the Digital Cinema Camera "ZR," which combines technologies from Nikon and RED Digital Cinema, Inc. The company aims to develop the professional video market as a new pillar of revenue for the Imaging Products Business, diversifying earnings away from dependence on the mid- to high-end camera market. This is positioned as one of the priority investment areas under the new medium-term management plan (FY2026–FY2030 (ending March 2030)).
Nikon has begun taking orders for the "DSP-100," its first digital lithography system for semiconductor back-end processes. By expanding into back-end process products in addition to ArF immersion lithography systems, the company aims to broaden the market scope of the Precision Equipment Business and strengthen its ability to capture AI-related semiconductor demand. ArF immersion lithography and digital lithography are designated as priority investment areas in the new medium-term management plan.
The company continues to increase unit sales of large-format metal 3D printers through Nikon SLM Solutions AG (revenue up 20.3% year on year in FY2026 (ending March 2026)), capturing expanding demand in the defense and space domains, primarily in the United States. However, a large-scale impairment loss of ¥90,627 million was recorded in FY2026 (ending March 2026), making a fundamental improvement in the earnings structure a prerequisite. This area is positioned as a priority investment area in the new medium-term management plan, with management resources to be allocated while emphasizing the balance sheet and cash flow.
Under the new medium-term management plan covering FY2026 through FY2030 (ending March 2030), the company will concentrate management resources on three priority fields while emphasizing the balance sheet and cash flow. The aim is to enhance corporate value by balancing near-term earnings recovery with investment for long-term growth. For FY2027 (ending March 2027), the company forecasts revenue of ¥740,000 million, operating profit of ¥10,000 million, and an annual dividend of ¥20 (total payout ratio of 60% or more).
Last updated: July 19, 2026

